Sortera's game changing approach to drug discovery sets the standard for the future of biologics. Deep Screening, our breakthrough technology, generates massive sequence-function datasets that power AI models, giving us unmatched speed and control over the discovery process.
There is a scarcity of high quality, unbiased, real-world data for training machine learning models to design novel biologics. Sortera's Deep Screening platform solves this problem by collecting hundreds of millions of sequence-function pairs from a single experiment.
Unlock better leads faster, no matter your starting point. Deep Screening enables comprehensive analysis of antibody libraries - whether enriched through in vitro, in vivo, or in silico discovery methods - including against challenging membrane protein targets.
At Sortera, we partner with world-leading companies to address the toughest challenges in biologics discovery. We welcome opportunities to leverage Deep Screening and develop groundbreaking biologics.
